Mendus – executive interview

In this video, we speak with Erik Manting, CEO of Mendus, and Tariq Mughal, CMO, where we discuss the company’s recently announced renewed strategy for lead cancer vaccine, vididencel. Erik and Tariq cover what drove the updated strategy and why now, including the potential of vididencel to expand its application in both acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML). They cover the company’s plans for new Phase I studies (and subsequent trials) in these new settings, and also discuss Mendus’s collaboration with a biopharmaceutical company to explore vididencel in combination with targeted therapies. The interview concludes with a summary of the expected timelines associated with the company’s new plans, alongside key milestones and catalysts to watch out for across the next 12–18 months

Mendus is a Sweden-based immuno-oncology company specialised in the field of allogeneic dendritic cell biology. Its leading clinical candidate is vididencel, an off-the-shelf cell-based cancer vaccine, which is being evaluated as a potential maintenance treatment for AML, CML and ovarian cancer.